Henry Koiti Sato

Henry Koiti Sato

Auto-generated profile, based on publicly available information

Henry Koiti Sato

Instituto de Neurologia de Curitiba, Departamento de Neurologia Clínica, Curitiba PR, Brazil

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2021 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
SASamira Luisa Apostolos-Pereira
Samira Luisa Apostolos-Pereira
LFLis Campos Ferreira
Lis Campos Ferreira
MBMateus Boaventura
Mateus Boaventura
NSNise Alessandra de Carvalho Sousa
Nise Alessandra de Carvalho Sousa
GMGabriela Joca Martins
Gabriela Joca Martins
FGFelipe von Glehn
Felipe von Glehn
Background and Objectives To describe the clinical features and disease outcomes of coronavirus disease 2019 (COVID-19) in patients with neuromyelitis optica spectrum disorder (NMOSD). Methods The Neuroimmunology Brazilian Study Group has set up the report of severe acute respiratory syndrome (SARS-CoV2) cases in patients with NMOSD (pwNMOSD) using a designed web-based case report form. All neuroimmunology outpatient centers and individual neurologists were invited to register their patients across the country. Data collected between March 19 and July 25, 2020, were uploaded at the REDONE.br platform. Inclusion criteria were as follows: (1) NMOSD diagnosis according to the 2015 International Panel Criteria and (2) confirmed SARS-CoV2 infection (reverse transcription-polymerase chain reaction or serology) or clinical suspicion of COVID-19, diagnosed according to Center for Disease Control / Council of State and Territorial Epidemiologists (CDC/CSTE) case definition. Demographic and NMOSD-related clinical data, comorbidities, disease-modifying therapy (DMT), COVID-19 clinical features, and severity were described. Results Among the 2,061 pwNMOSD followed up by Brazilian neurologists involved on the registry of COVID-19 in pwNMOSD at the REDONE.br platform, 34 patients (29 women) aged 37 years (range 8–77), with disease onset at 31 years (range 4–69) and disease duration of 6 years (range 0.2–20.5), developed COVID-19 (18 confirmed and 16 probable cases). Most patients exhibited mild disease, being treated at home (77%); 4 patients required admission at intensive care units (severe cases); and 1 patient died. Five of 34 (15%) presented neurologic manifestations (relapse or pseudoexacerbation) during or after SARS-CoV2 infection. Discussion Most NMOSD patients with COVID-19 presented mild disease forms. However, pwNMOSD had much higher odds of hospitalization and intensive care unit admission comparing with the general Brazilian population. The frequency of death was not clearly different. NMOSD disability, DMT type, and comorbidities were not associated with COVID-19 outcome. SARS-CoV2 infection was demonstrated as a risk factor for NMOSD relapses. Collaborative studies using shared NMOSD data are needed to suitably define factors related to COVID-19 severity and neurologic manifestations.

1 November 2021 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
JBJefferson Becker
Jefferson Becker
LFLis Campos Ferreira
Lis Campos Ferreira
ADAlfredo Damasceno
Alfredo Damasceno
DBDenis Bernardi Bichuetti
Denis Bernardi Bichuetti
PCPaulo Pereira Christo
Paulo Pereira Christo
FGFelipe von Glehn
Felipe von Glehn
The Scientific Department of Neuroimmunology of the Brazilian Academy of Neurology (DCNI/ABN) and Brazilian Committee for Treatment and Research in Multiple Sclerosis and Neuroimmunological Diseases (BCTRIMS) provide recommendations in this document for vaccination of the population with demyelinating diseases of the central nervous system (CNS) against infections in general and against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19. We emphasize the seriousness of the current situation in view of the spread of COVID-19 in our country. Therefore, reference guides on vaccination for clinicians, patients, and public health authorities are particularly important to prevent some infectious diseases. The DCNI/ABN and BCTRIMS recommend that patients with CNS demyelinating diseases (e.g., MS and NMOSD) be continually monitored for updates to their vaccination schedule, especially at the beginning or before a change in treatment with a disease modifying drug (DMD). It is also important to note that vaccines are safe, and physicians should encourage their use in all patients. Clearly, special care should be taken when live attenuated viruses are involved. Finally, it is important for physicians to verify which DMD the patient is receiving and when the last dose was taken, as each drug may affect the induction of immune response differently.

3 May 2016 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
PDF file
YFYara Dadalti Fragoso
Yara Dadalti Fragoso
HSHenry Koiti Sato
Henry Koiti Sato

15 July 2025 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
ADAlfredo Damasceno
Alfredo Damasceno
Cintia Ramari FerreiraCintia Ramari Ferreira
Cintia Ramari Ferreira
CTCarlos Tauil
Carlos Tauil
HSHenry Koiti Sato
Henry Koiti Sato
DCDagoberto Callegaro
Dagoberto Callegaro
JBJefferson Becker
Jefferson Becker
Multiple sclerosis (MS) is an inflammatory and neurodegenerative disorder whose prevalence varies across Brazil (from 15–27 cases per 100 thousand inhabitants), and the absence of an extensive national study limits the understanding of MS epidemiology in a nation as diverse as Brazil. To compare epidemiological data, including healthcare access, among people with MS across four Brazilian regions. Data from 2,974 Brazilian MS patients in the Collaborative Latin American Database for Multiple Sclerosis (BRANDO) were analyzed. We assessed demographic and clinical outcomes, as well as healthcare access, to elucidate regional differences. The cohort was predominantly composed of female patients (72.5%) with MS onset at a mean age of 30.6 years. Regarding the regional differences, there was a lower predominance of female patients (68.7%; p = 0.003) in the Southeast, a higher rate of subjects of mixed ethnicity (p < 0.001) in the Midwest (40.3%) and Northeast (63.7%), higher scores on the Expanded Disability Status Scale (EDSS) in the Northeast (4.0; p < 0.001), a higher prevalence of relapsing-remitting MS (RRMS) in the Southeast and Midwest (87%; p < 0.001), while the Northeast presented (p < 0.001) the highest rates of primary progressive MS (PPMS) and secondary progressive MS (SPMS) (PPMS = 15.8%; SPMS = 18%). The Northeast presented the longest time (5.9 years; p < 0.01) from disease onset until MS diagnosis (range for the other regions = 1.9–3.7 years). And the Midwest showed the shortest time (2.1 years; p < 0.01) from disease onset until first access to disease-modifying therapies (DMTs; range for the other regions = 3.5–5.1 years). The present is the first nationwide epidemiological study on people with MS in Brazil. It underscores regional epidemiological variations and differences in healthcare access, advocating for tailored approaches in MS management and research.

9 December 2019 in Psicologia Argumento
Verified
Journal Article
Open access
PDF file
MAMariana Kaspchak Arent
Mariana Kaspchak Arent
APAna Paula Almeida de Pereira
Ana Paula Almeida de Pereira
HSHenry Koiti Sato
Henry Koiti Sato
CJClovis Gomes Jr
Clovis Gomes Jr
A Esclerose múltipla (EM) é considerada uma doença crônica que acomete mais frequentemente jovens adultos. Estima-se que 2,3 milhões de pessoas no mundo são afetadas pela doença. Pessoas com EM costumam apresentar alterações cognitivas e na sua qualidade de vida. A presente pesquisa visa identificar e discutir os instrumentos de avaliação neuropsicológica utilizados atualmente com pessoas com diagnóstico de EM. Para tanto, foi realizada uma revisão sistemática da literatura cientifica. Este estudo mostrou a importância da investigação das funções cognitivas em pessoas com diagnóstico de EM. As baterias breves mais utilizadas evidenciadas na revisão sistemática são Brief International Cognitive Assessment of Multiple Sclerosis (BICAMS), Multiple Sclerosis Functional Composite Measure (MSFC) e Brief Repeatable Battery of Neuropsychological Test (BNR-N). Os testes mais utilizados na avaliação neuropsicológica de paciente com EM são PASAT e SDMT, que enfocam a avaliação da velocidade de processamento.

16 March 2018 in JBNC - JORNAL BRASILEIRO DE NEUROCIRURGIA
Verified
Journal Article
Open access
PDF file
HSHenry Koiti Sato
Henry Koiti Sato
MNMaurício Coelho Neto
Maurício Coelho Neto
EJErasmo Barros Da Silva Jr
Erasmo Barros Da Silva Jr
LJLuis Fernando Moura Da Silva Junior
Luis Fernando Moura Da Silva Junior
RRRicardo Ramina
Ricardo Ramina
Introduction: Resection of gliomas in eloquent areas such as motor and supplementary motor areas has always been a main challenge for the surgeon due to the risk of severe neurological sequelae. An important tool used during the procedure to avoid postoperative deficits is the intraoperative cortical stimulation of eloquent areas as a safe option of functional area mapping. Methods: In this study, authors examined 50 patients with gliomas located in the motor and supplementary motor area that have undergone surgery with cortical stimulation, using clinical assessment of muscle strength in the pre- and immediate postoperative assessments and three months after surgery as parameters. Results: There was significant difference (p<0.001) between the preoperative and immediate postoperative assessments regarding the occurrence of severe neurological deficit, demonstrating a worsening of the neurological status after surgery. Concerning the comparison between the immediate postoperative period and the assessment performed three months after surgery, it was observed that all the patients who had severe deficit (11 cases) improved (p<0.001). No statistical difference was found between the malignancy grade and the evolution of the neurological deficit in the assessments performed in the three evaluated periods. Conclusion: In the immediate postoperative period following surgical resection of glial tumors in the motor and supplementary motor areas with intraoperative cortical monitoring, most patients have significant alterations in their muscle strength. However, three months after surgery there was significant improvement of these neurological deficits and no patient had severe sequelae.